The global human papillomavirus vaccine (HPV) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). There are more than 100 HPV, among which 14 are cancer-causing. According to the WHO, HVP 16 and 18 types are responsible for around 70% of cervical cancer and pre-cancerous cervical lesions. The rising incidences of HPV associated cancers of the anus, vulva, vagina, penis, and oropharynx and increasing demand for prevention of these infections are the major factors that are augmenting the growth of the market during the forecast period. Moreover, government initiatives for HPV vaccination programs are anticipated to boost the market growth during the forecast period. Since June 2020, around 55% of the WHO Member States have introduced HPV vaccination. Furthermore, increasing healthcare infrastructure and expenditure in emerging countries is expected to generate untapped opportunities for the market participants. However, the stringent government regulations associated with manufacturing new vaccines are anticipated to hamper the market growth.
To Request a Sample of our Report on Human Papillomavirus Vaccine (HPV) Market: https://www.omrglobal.com/request-sample/human-papillomavirus-vaccine-hpv-market
HPV vaccines protect against infection with human papillomaviruses (HPV). HPV is a group of more than 200 related viruses, of which more than 40 are spread through direct sexual contact. Among these, two HPV types cause genital warts, and about a dozen HPV types can cause certain types of cancer associated with cervical, anal, oropharyngeal, penile, vulvar, and vaginal. In order to maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions.
Recent Developments:
· In July 2020, the US Food and Drug Administration (FDA) approved an expanded indication for Merck’ Gardasil 9, a human papillomavirus (HPV) nine-valent vaccine, for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
· In March 2020, the HPV vaccine, Cecolin by Innovax was officially accepted by the WHO for the prequalification evaluation.
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered-
· By Type
· By Distribution Channel
• Regions covered–
· North America
· Europe
· Asia-Pacific
· Rest of the World
· Competitive Landscape: Merck & Co., Inc., GlaxoSmithKline Plc, and Sanofi S.A., among others.
(Get 15% Discount on Buying this Report)
A full Report of Human Papillomavirus Vaccine (HPV) Market is Available @ https://www.omrglobal.com/industry-reports/human-papillomavirus-vaccine-hpv-market
Global HPV Vaccine Market Report by Segment
By Type
• Bivalent
• Polyvalent
By Distribution Channel
• Hospitals
• Clinics
· Government Entities
Global HPV Vaccine Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
· Latin America
· Middle East & Africa
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
